Hostname: page-component-586b7cd67f-dsjbd Total loading time: 0 Render date: 2024-11-29T16:22:09.796Z Has data issue: false hasContentIssue false

Myocarditis in drug rash with eosinophilia and systemic symptoms

Published online by Cambridge University Press:  19 September 2014

Cynthia H. Ho*
Affiliation:
Department of Pediatrics, Keck School of Medicine, Los Angeles County + University of Southern California Medical Center, Los Angeles, California, United States of America Department of Internal Medicine, Keck School of Medicine, Los Angeles County + University of Southern California Medical Center, Los Angeles, California, United States of America
Merujan Y. Uzunyan
Affiliation:
Department of Pediatrics, Keck School of Medicine, Los Angeles County + University of Southern California Medical Center, Los Angeles, California, United States of America Division of Cardiology, Keck School of Medicine, Los Angeles County + University of Southern California Medical Center, Los Angeles, California, United States of America
*
Correspondence to: C. H. Ho, MD, Keck School of Medicine, Los Angeles County+University of Southern California Medical Center, 2020 Zonal Avenue, IRD Room 109, Los Angeles, CA 90033, United States of America. Tel: +323 226 3691; Fax: +323 226 5692; E-mail: [email protected]

Abstract

Drug rash with eosinophilia and systemic symptoms is a drug hypersensitivity reaction. Hepatitis and nephritis are the most common visceral manifestations. Myocarditis is important to recognise, given the high mortality rate. We describe a child with drug rash with eosinophilia and systemic symptoms and discuss the role of N-terminal pro-hormone of basic natriuretic peptide in early recognition of associated myocarditis.

Type
Brief Reports
Copyright
© Cambridge University Press 2014 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Kardaun, SH, Sekula, P, Valeyrie-Allanore, L, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol 2013; 169: 10711080.CrossRefGoogle ScholarPubMed
2. Shiohara, T, Inaoka, M, Kano, Y. Drug-induced hypersensitivity syndrome (DIHS): a reaction induced by a complex interplay among herpesviruses and antiviral and antidrug immune responses. Allerg Int 2006; 55: 18.Google Scholar
3. Bourgeois, GP, Cafardi, JA, Groysman, V, Hughey, LC. A review of DRESS-associated myocarditis. J Am Acad Dermatol 2012; 66: e229e236.CrossRefGoogle ScholarPubMed
4. Bourgeois, GP, Cafardi, JA, Groysman, V, et al. Fulminant myocarditis as a late sequelae of DRESS – 2 cases. J Am Acad Dermatol 2011; 65: 889890.Google Scholar
5. Nir, A, Lindinger, A, Rauh, M, et al. NT-Pro-B-type natriuretic peptide in infants and children: reference values based on combined data from four studies. Pediatr Cardiol 2009; 30: 38.CrossRefGoogle ScholarPubMed
6. Nasser, N, Perles, Z, Rein, AJ, Nir, A. NT-proBNP as a marker for persistent cardiac disease in children with a history of dilated cardiomyopathy and myocarditis. Pediatr Cardiol 2006; 27: 8790.CrossRefGoogle ScholarPubMed
7. Mlczoch, E, Darbandi-Mesri, F, Luckner, D, Salzer-Muhar, U. NT-pro BNP in acute childhood myocarditis. J Pediatr 2012; 160: 178179.Google Scholar
8. Joly, P, Janela, B, Tetart, F, et al. Poor benefit/risk balance of intravenous immunoglobulins in DRESS. Arch Dermatol 2012; 148: 543544.Google Scholar
9. Singer, EM, Wanat, KA, Rosenbach, MA. A case of recalcitrant DRESS syndrome with multiple autoimmune sequelae treated with intravenous immunoglobulins. JAMA Dermatol 2013; 149: 494495.CrossRefGoogle ScholarPubMed
10. Chopra, S, Levell, NJ, Conley, G, Gilkes, JJ. Systemic corticosteroids in the phenytoin hypersensitivity syndrome. Br J Dermatol 1996; 134: 11091112.Google Scholar